A nationally representative study among patients enrolled in Medicare, who were diagnosed with cancer, found that out-of-pocket costs averaged at 23.7% of their household income. A majority of these costs could be attributed to hospitalization.
A nationally representative study among patients enrolled in Medicare, who were diagnosed with cancer, found that out-of-pocket (OOP) costs averaged at 23.7% of their household income. More significantly, 10% of patients incurred costs that were a little over 63% of their total family income.
The authors of this JAMA Oncology study collected survey data from 18,166 Medicare enrollees, 1409 of whom were diagnosed with cancer during the study period marked between January 1, 2002, and December 31, 2012. The primary outcome being evaluated was OOP costs and financial burden (OOP expenditure divided by the household income).
With a fairly even distribution of males and females, supplementary insurance showed a strong association with the mean annual OOP costs following a cancer diagnosis, among the 1409 individuals. Specifically, the following costs were documented:
A new cancer diagnosis was also associated with greater odds of higher OOP costs, the authors found (adjusted odds ratio, 1.86; 95% CI, 1.55-2.23; P < .001). The 10% of patients with cancer who had the highest OOP costs found hospitalization a major drain on their wallet, accounting for 41.6% of their overall OOP expenditure.
Based on their findings, the authors propose a Medicare benefit redesign for hospital-based services, in addition to a cap on maximum OOP costs for Medicare beneficiaries. Additionally, they also recommend interventions that can reduce hospitalizations among these individuals.
The community-based medical home model has always been a strong proponent of keeping patients out of the hospital. Using an in-house triage system and a triage nurse to help direct patient calls and even provide 27/7 medical advice, Barbara McAneny, MD, chief executive officer, New Mexico Cancer Center & Innovative Oncology Business Solutions, has developed the COME HOME model for oncology care, all in an effort to render patient-centered care while keeping costs down.
“We have to be able to manage the patients, have to ensure that they get what they need, and we need to have an adequate system in place to support the process. This will help keep patients out of the hospital and to keep the costs low,” McAneny said at The Community Oncology Conference: Innovation in Cancer Care, earlier this year.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More